APOA1 and metabolic syndrome: Having all of the above properties, apoA-I is a promising candidate for both the inclusion in serum-free media for MSCs propagation and as a therapeutic agent for transplantation of MSCs to treat atherosclerosis-associated disease, such as CVD, myocardial infarction, diabetes, metabolic syndrome, and rheumatoid arthritis.